Advances in Glioma Temozolomide-Resistance Regulated by MicroRNA

doi:10.3877/cma.j.issn.2095-9141.2016.04.012

Abstract

Abstract:

MicroRNAs(miRNA) are small non-coding RNAs of endogenous small molecules, which are important to regulate the post-transcription of gene expression. MiRNAs in glioma drug resistance has been explored and researched, found that the miRNA plays an important role in drug resistance. Currently, we made a systematic review of the miRNA and Glioma for Temozolomide (TMZ) chemotherapy drug resistance gene for promoting specific pathways in Glioma of new targeted therapy of the further development.

Key words: MicroRNA, Glioma, Temozolomide

Yongming Xu, Hongqin Wang. Advances in Glioma Temozolomide-Resistance Regulated by MicroRNA[J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2016, 02(04): 241-244.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsjcswkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9141.2016.04.012

https://zhsjcswkdzzz.cma-cmc.com.cn/EN/Y2016/V02/I04/241

References 43

[1]	Brodbelt A,Greenberg D,Winters T, et al. Glioblastoma in England: 2007-2011[J]. Eur J Cancer, 2015, 51(4): 533-542.
[2]	Desjardins A,Vlahovic G,Friedman HS. Vaccine Therapy,Oncolytic Viruses, and Gliomas[J]. Oncology (Williston Park), 2016, 30(3): 211-218.
[3]	Zhou X,Ren Y,Moore L, et al. Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status[J]. Lab Invest, 2010, 90(2): 144-155.
[4]	Miglierini P,Bouchekoua M,Rousseau B, et al. Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity[J]. Clin Neurol Neurosurg, 2012, 114(9): 1222-1225.
[5]	Plowman J,Waud WR,Koutsoukos AD, et al. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1, 3-bis(2-chloroethyl)-1-nitrosourea[J]. Cancer Res, 1994, 54(14): 3793-3799.
[6]	McFaline-Figueroa JL,Braun CJ,Stanciu M, et al. Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide[J]. Cancer Res, 2015, 75(15): 3127-3138.
[7]	Feng R,Dong L. Knockdown of microRNA-127 reverses adriamycin resistance via cell cycle arrest and apoptosis sensitization in adriamycin-resistant human glioma cells[J]. Int J Clin Exp Pathol, 2015, 8(6): 6107-6116.
[8]	Munoz JL,Rodriguez-Cruz V,Ramkissoon SH, et al. Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level[J]. Oncotarget, 2015, 6(2): 1190-1201.
[9]	Shi L,Zhang S,Feng K, et al. MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis[J]. Int J Oncol, 2012, 40(1): 119-129.
[10]	Wu H,Liu Q,Cai T, et al. MiR-136 modulates glioma cell sensitivity to temozolomide by targeting astrocyte elevated gene-1[J]. Diagn Pathol, 2014, 9: 173.
[11]	Li P,Lu X,Wang Y, et al. MiR-181b suppresses proliferation of and reduces chemoresistance to temozolomide in U87 glioma stem cells[J]. J Biomed Res, 2010, 24(6): 436-443.
[12]	Quintavalle C,Mangani D,Roscigno G, et al. MiR-221/222 target the DNA methyltransferase MGMT in glioma cells[J]. PLoS One, 2013, 8(9): e74466.
[13]	Lee RC,Feinbaum RL,Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14[J]. Cell, 1993, 75(5): 843-854.
[14]	Mestdagh P,Hartmann N,Baeriswyl L, et al. Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study[J]. Nat Methods, 2014, 11(8): 809-815.
[15]	Stahlhut Espinosa CE,Slack FJ. The role of microRNAs in cancer[J]. Yale J Biol Med, 2006, 79(3-4): 131-140.
[16]	Shen J,Hung MC. Signaling-mediated regulation of MicroRNA processing[J]. Cancer Res, 2015, 75(5): 783-791.
[17]	Khorkova O,Myers AJ,Hsiao J, et al. Natural antisense transcripts[J]. Hum Mol Genet, 2014, 23(R1): R54-R63.
[18]	Garajova I,Le Large TY,Giovannetti E, et al. The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment: Translational Studies and Basic Protocols for Extraction and PCR Analysis[J]. Methods Mol Biol, 2016, 1395: 163-187.
[19]	Esquela-Kerscher A,Slack FJ. Oncomirs-microRNAs with a role in cancer[J]. Nat Rev Cancer, 2006, 6(4): 259-269.
[20]	Weber F,Teresi RE,Broelsch CE, et al. A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma[J]. J Clin Endocrinol Metab, 2006, 91(9): 3584-3591.
[21]	Ling H,Fabbri M,Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development[J]. Nat Rev Drug Discov, 2013, 12(11): 847-865.
[22]	Gottesman MM. Mechanisms of cancer drug resistance[J]. Annu Rev Med, 2002, 53: 615-627.
[23]	Khamisipour G,Jadidi-Niaragh F,Jahromi AS, et al. Mechanisms of tumor cell resistance to the current targeted-therapy agents[J]. Tumour Biol, 2016.
[24]	Rigalli JP,Ciriaci N,Mottino AD, et al. Modulation of expression and activity of ABC transporters by the phytoestrogen genistein. Impact on drug disposition[J]. Curr Med Chem, 2016, 23(13): 1370-13789.
[25]	Berman M,Mattheolabakis G,Suresh M, et al. Reversing epigenetic mechanisms of drug resistance in solid tumors using targeted microRNA delivery[J]. Expert Opin Drug Deliv, 2016, 13(7): 987-998.
[26]	Tomimaru Y,Eguchi H,Nagano H, et al. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-alpha/5-fluorouracil in hepatocellular carcinoma cells[J]. Br J Cancer, 2010, 103(10): 1617-1626.
[27]	Chan XH,Nama S,Gopal F, et al. Targeting glioma stem cells by functional inhibition of a prosurvival oncomiR-138 in malignant gliomas[J]. Cell Rep, 2012, 2(3): 591-602.
[28]	Stojcheva N,Schechtmann G,Sass S, et al. MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM[J]. Oncotarget, 2016, 7(11): 12937-12950.
[29]	Calin GA,Dumitru CD,Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia[J]. Proc Natl Acad Sci USA, 2002, 99(24): 15524-15529.
[30]	Aqeilan RI,Calin GA,Croce CM. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives[J]. Cell Death Differ, 2010, 17(2): 215-220.
[31]	Kasar S,Underbayev C,Hassan M, et al. Alterations in the mir-15a/16-1 Loci Impairs Its Processing and Augments B-1 Expansion in De Novo Mouse Model of Chronic Lymphocytic Leukemia (CLL)[J]. PLoS One, 2016, 11(3): e149331.
[32]	Porkka KP,Ogg EL,Saramaki OR, et al. The miR-15a-miR-16-1 locus is homozygously deleted in a subset of prostate cancers[J]. Genes Chromosomes Cancer, 2011, 50(7): 499-509.
[33]	Lan F,Yue X,Ren G, et al. miR-15a/16 enhances radiation sensitivity of non-small cell lung cancer cells by targeting the TLR1/NF-kappaB signaling pathway[J]. Int J Radiat Oncol Biol Phys, 2015, 91(1): 73-81.
[34]	Han J,Chen Q. MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells[J]. Int J Clin Exp Pathol, 2015, 8(10): 12698-12707.
[35]	Shi L,Zhang S,Feng K, et al. MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis[J]. Int J Oncol, 2012, 40(1): 119-129.
[36]	Cairo S,Wang Y,de Reynies A, et al. Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer[J]. Proc Natl Acad Sci USA, 2010, 107(47): 20471-20476.
[37]	Shi L,Zhang J,Pan T, et al. MiR-125b is critical for the suppression of human U251 glioma stem cell proliferation[J]. Brain Res, 2010, 1312: 120-126.
[38]	Kim JT,Kim JS,Ko KW, et al. Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas[J]. Oncol Rep, 2006, 16(1): 33-39.
[39]	Chen J,Fu X,Wan Y, et al. miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1[J]. Tumour Biol, 2014, 35(7): 6293-6302.
[40]	Le MT,Teh C,Shyh-Chang N, et al. MicroRNA-125b is a novel negative regulator of p53[J]. Genes Dev, 2009, 23(7): 862-876.
[41]	Zhang Z,Zhang B,Li W, et al. Epigenetic Silencing of miR-203 Upregulates SNAI2 and Contributes to the Invasiveness of Malignant Breast Cancer Cells[J]. Genes Cancer, 2011, 2(8): 782-791.
[42]	Li Y,Yuan Y,Tao K, et al. Inhibition of BCR/ABL protein expression by miR-203 sensitizes for imatinib mesylate[J]. PLoS One, 2013, 8(4): e61858.
[43]	Tang G,Wu J,Xiao G, et al. MiR-203 sensitizes glioma cells to temozolomide and inhibits glioma cell invasion by targeting E2F3[J]. Mol Med Rep, 2015, 11(4): 2838-2844.

Please choose a citation manager

Content to export